宫内暴露后脐带血中蛋白酶抑制剂的浓度。
Concentrations of protease inhibitors in cord blood after in utero exposure.
作者信息
Mirochnick Mark, Dorenbaum Alex, Holland Diane, Cunningham-Schrader Bethann, Cunningham Colleen, Gelber Richard, Mofenson Lynne, Culnane Mary, Connor James, Sullivan John L
机构信息
Boston University School of Medicine, and Statistical and Data Analysis Center/Harvard School of Public Health, Boston, MA, USA.
出版信息
Pediatr Infect Dis J. 2002 Sep;21(9):835-8. doi: 10.1097/00006454-200209000-00010.
OBJECTIVE
To determine the concentrations of protease inhibitors in cord blood after prenatal protease inhibitor use by pregnant women.
DESIGN
Retrospective analysis of samples collected in a clinical trial.
METHODS
Protease inhibitor concentrations were measured in cord blood samples collected from women enrolling in the PACTG 316 study who were receiving prenatal protease inhibitor antiretroviral therapy.
RESULTS
In cord blood samples from 68 women treated with protease inhibitors during pregnancy, the concentration of these drugs was below the assay lower limit of detection in most samples, including all samples from women receiving indinavir (n = 21) and saquinavir (n = 8), 5 of 6 samples (83%) from women receiving ritonavir and 24 of 38 samples (63%) from women receiving nelfinavir.
CONCLUSIONS
Low protease inhibitor concentrations in the fetus decrease the likelihood of teratogenic and toxic effects of these drugs but could fail to provide protection from transplacental or intrapartum transmission of HIV-1.
目的
确定孕妇产前使用蛋白酶抑制剂后脐带血中蛋白酶抑制剂的浓度。
设计
对一项临床试验中收集的样本进行回顾性分析。
方法
在参与PACTG 316研究且接受产前蛋白酶抑制剂抗逆转录病毒治疗的女性所采集的脐带血样本中测量蛋白酶抑制剂浓度。
结果
在孕期接受蛋白酶抑制剂治疗的68名女性的脐带血样本中，这些药物的浓度在大多数样本中低于检测下限，包括接受茚地那韦（n = 21）和沙奎那韦（n = 8）的女性的所有样本、接受利托那韦的女性的6个样本中的5个（83%）以及接受奈非那韦的女性的38个样本中的24个（63%）。
结论
胎儿体内蛋白酶抑制剂浓度较低降低了这些药物致畸和产生毒性作用的可能性，但可能无法预防HIV-1的经胎盘或分娩时传播。
Zotero 插件